UK's Feedback Plc anticipates NHS funding opportunities starting April 2026

Feedback

17/02/2026 07:16

Overview

Clinical infrastructure specialist's H1 revenue stable yr/yr

EBITDA loss increased due to new hires and technology costs

Company positioned for growth with strategic partnerships and NHS engagements

Outlook

Feedback anticipates NHS funding opportunities starting April 2026

Company is pausing operations in India to focus on UK market

Feedback aims to roll out Bleepa nationally through strategic partnerships

Result Drivers

BLEEPA INTEGRATION - Co completed integrations into NHS systems like eRS, PDS, and GP Connect, positioning for national scale

COST INCREASES - EBITDA loss increased due to new support team hires and technology costs for cloud solutions

STRATEGIC PARTNERSHIPS - Co in late-stage discussions for partnerships to support Bleepa's rollout

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
GBP 413,000
H1 EBIT
-GBP 1.79 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Feedback PLC is GBp60.00, about 466% above its February 16 closing price of GBp10.60

Press Release: ID:nRSQ2356Ta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)